Supplier News Breaks Archives
FluMist joins vaccine lineup at FFF Enterprises
February 8th, 2011
TEMECULA, Calif. – FFF Enterprises Inc. has added FluMist flu vaccine nasal spray to its portfolio of flu immunizations.
The vaccine and biopharmaceuticals company said Monday that it will be supplying FluMist on a wide contractual basis to its GPO partner members, as well as to consumers through community vaccinator VaxAmerica, a program of FFF Specialty Pharmacy NuFACTOR.
"We are very pleased to introduce FluMist, a live attenuated influenza vaccine, to our portfolio of inactivated influenza vaccine injectable products, rounding out our selection of products from the most respected manufacturers," commented Patrick Schmidt, chief executive officer of FFF Enterprises.
FluMist, manufactured by AstraZeneca subsidiary MedImmune, is approved for eligible, healthy people between the ages 2 and 49. In 2010, the Centers for Disease Control and Prevention expanded their recommendations for annual influenza vaccination to include all people age 6 months and older to get a seasonal flu vaccine, and FFF Enterprises noted that health care providers can help improve compliance by being able to offer patients the choice of a spray in the nose or a shot in the arm.
"For most people, getting immunized against influenza is the easiest and most effective way to reduce their risk of infection," stated Schmidt. "By offering FluMist, health care providers can give patients more options and increase vaccination rates."